Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
C01 EB17
|
| gptkbp:brand |
gptkb:Firazyr
|
| gptkbp:casnumber |
169590-42-5
|
| gptkbp:chemical_formula |
C59 H84 N14 O13 S
|
| gptkbp:clinical_trial |
Phase III
|
| https://www.w3.org/2000/01/rdf-schema#label |
Icatibant
|
| gptkbp:mechanism_of_action |
bradykinin receptor antagonist
|
| gptkbp:used_for |
treatment of hereditary angioedema
|
| gptkbp:bfsParent |
gptkb:Cinryze
|
| gptkbp:bfsLayer |
6
|